About FID-022

FID-022 is composed of topoisomerase inhibitors encapsulated with a polyethyloxazoline polymer using our nanoencapsulation platform and our nano-drug delivery technology. FID-022 exhibited superior tumor reductions when compared to irinotecan in various xenograft cancer models, including colon, bile duct, ovarian, and pancreatic cancers, while showing no significant unexpected toxicity observed in both rat and monkey under Good Laboratory Practice (GLP) toxicity studies.

A Phase 1 Investigational New Drug (IND) application for FID-022 focusing on the safety and tolerability of FID-022 in patients with advanced solid tumors has been approved by the US FDA and we expect to dose the first patient in mid-2025.

For more information, please see Clinical Trial titled “A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors” (Phase 1, ClinicalTrials.gov ID NCT06694480, https://clinicaltrials.gov/study/NCT06694480).